TR
TRAW.O
—
NASDAQ
Biotechnology & Life-Science Tools
Traws Pharma Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
7,3M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
-640,7 %
ROE
-1 457,9 %
Net margin
328,7 %
Debt / equity
0,00
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$0,45
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Traws Pharma Inc is a biotechnology company focused on healthcare diagnostics, developing and commercializing diagnostic solutions for disease detection and monitoring.
Business. Traws Pharma Inc (NASDAQ: TRAW.O) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm generates revenue through product sales and is headquartered in the United States. Specific details regarding operating segments and geographic revenue mix are not available. The company is primarily listed on the NASDAQ stock exchange.
Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
Generated · model-assisted
Sell-side consensus
HOLD2 analysts
0 buy2 hold0 sell
Avg 12m price target1,00
Analyst recommendations
2 analysts · consensus HoldBuy0
Hold2
Sell0
12-month price target
1,00
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Hold
2 analysts · indicative
Ownership→
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability→
-1 457,9 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to TRAW.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Traws Pharma Inc (NASDAQ: TRAW.O) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm generates revenue through product sales and is headquartered in the United States. Specific details regarding operating segments and geographic revenue mix are not available. The company is primarily listed on the NASDAQ stock exchange.
Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
AI synthesis
GENERATEDTraws Pharma Inc has a market capitalization of $22.57 million and a price-to-earnings ratio of 2.46, indicating a relatively low valuation compared to earnings. The company's liquidity position is characterized by $3.82 million in cash and equivalents, but its total liabilities exceed total assets by $629,000, resulting in a negative equity position. The current ratio of 0.72 suggests the company may struggle to meet short-term obligations with its current assets.
Profitability metrics reveal a challenging financial landscape for Traws Pharma Inc. The company reported a net income of $9.17 million, but its operating income was a loss of $17.88 million, indicating significant operational inefficiencies. The return on equity is -14.58%, reflecting the negative equity position and poor returns for shareholders. The return on assets is 0.86%, which is low and suggests that the company is not effectively utilizing its assets to generate profit.
Traws Pharma Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification reported. This lack of diversification increases the company's exposure to market-specific risks and could impact its ability to sustain revenue growth in the long term.
The company's growth trajectory is mixed. While it reported a net income of $9.17 million, its operating cash flow was a loss of $18.19 million, indicating that the company is not generating sufficient cash from operations to support its activities. The free cash flow of $6.93 million suggests that the company has some flexibility in managing its cash, but this is offset by the negative operating cash flow.
Risk factors for Traws Pharma Inc include a low liquidity position and a negative equity balance, which could limit the company's ability to invest in growth opportunities or withstand financial downturns. The company has no immediate filing-based liquidity or dilution flags, but its financial structure suggests a potential need for external financing in the near term. The risk assessment indicates a low probability of dilution, but the company's financial position may necessitate equity issuance to fund operations.
Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's mean price target of $5.50, as estimated by analysts, suggests a positive outlook, but the wide range from $3.00 to $8.00 indicates uncertainty among analysts regarding the company's future performance.
Key takeaways
- Traws Pharma Inc has a low price-to-earnings ratio of 2.46, suggesting it is undervalued relative to its earnings.
- The company's negative equity position and low current ratio indicate potential liquidity challenges.
- Despite a net income of $9.17 million, the company's operating income is a loss of $17.88 million, highlighting operational inefficiencies.
- The company's revenue is concentrated in a single segment, increasing its exposure to market-specific risks.
- Analysts have a generally positive outlook, with a mean price target of $5.50, but the wide range of estimates reflects uncertainty.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$0,48
Market cap
$22.6M
Enterprise valueⓘ
$18.8M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
-$629.0k
Net cashⓘ
$3.8M
Current ratioⓘ
0.7
Debt / equityⓘ
0.0
ROAⓘ
86.4%
ROEⓘ
-14.6%
Cash conversionⓘ
-198.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs TRAW · multiples and returns
IQ
IQV—
Iqvia Holdings Inc
$181,94
30,9B USDP/E
22,7x
+22,2 vs self
Div yield
—
— vs self
ROE
21,9 %
+194,5 vs self
CR
CRL—
Charles River Laboratories
$230,87
11,4B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-4,6 %
+168,1 vs self
ME
MEDP—
Medpace Holdings Inc
$576,00
16,7B USDP/E
34,4x
+33,9 vs self
Div yield
—
— vs self
ROE
75,4 %
+248,1 vs self
AL
ALKS—
Alkermes PLC
$49,53
8,2B USDP/E
39,8x
+39,3 vs self
Div yield
—
— vs self
ROE
8,4 %
+181,1 vs self
PI
PIII—
P3 Health Partners Inc
$10,20
73,8M USDP/E
—
— vs self
Div yield
—
— vs self
ROE
95,3 %
+268,0 vs self
OR
ORGO—
Organogenesis Holdings Inc
$2,38
306,2M USDP/E
9,0x
+8,5 vs self
Div yield
—
— vs self
ROE
8,5 %
+181,2 vs self
NA
NAGE—
Niagen Bioscience Inc
$3,53
281,1M USDP/E
17,4x
+16,9 vs self
Div yield
—
— vs self
ROE
22,7 %
+195,4 vs self
SP
SPRY—
Ars Pharmaceuticals Inc
$5,51
547,1M USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-149,9 %
+22,7 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 67 %
EPS
Consensus EPS
-1,42
Predicted surprise
+0,08
Beat probability
67 %
Analysts
2
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
revision ratio 0,46 · as of 2026-08-03 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,42 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | -21,2M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution2 analysts
Strong buy0
Buy0
Hold2
Sell0
Strong sell0
12-month price target$1,00 · Median $1,00
Low $1,00High $1,00
Operating income · consensus-21,2M USD
EPS surprise
+380,4 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$1,00
Mean$1,00
Median$1,00
High$1,00
Spot$0,48
+107.9 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-640,7 %Below median
Net Margin328,7 %Above P75
ROE-1 457,9 %Bottom quartile
D/E0,00Above median
Cash Conv-1,98Bottom quartile
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 4 470 263 sh25 grants11 insiders
- 10% owner · Series B Warrants (right to buy) → Common StockAcquired 597 729 @ $1,67purchase · 2026-04-16
- 10% owner · Series C Warrants (right to buy) → Common StockAcquired 1 793 187 @ $1,67purchase · 2026-04-16
- 10% owner · Series A Warrants (right to buy) → Common StockAcquired 597 729 @ $1,67purchase · 2026-04-16
- Director · Stock Option (right to buy) → Common StockAcquired 33 435 @ $1,60grant · 2026-03-08
- Chief Financial Officer · Stock Option (right to buy) → Common StockAcquired 104 544 @ $1,60grant · 2026-03-08
- Director · Stock Option (right to buy) → Common StockAcquired 33 435 @ $1,60grant · 2026-03-08
- Director · Stock Option (right to buy) → Common StockAcquired 31 258 @ $1,60grant · 2026-03-08
- Director · Stock Option (right to buy) → Common StockAcquired 33 435 @ $1,60grant · 2026-03-08
- Director, Chief Executive Officer · Stock Option (right to buy) → Common StockAcquired 231 336 @ $1,60grant · 2026-03-08
- Chief Science Officer Virology · Stock Option (right to buy) → Common StockAcquired 118 367 @ $1,60grant · 2026-03-08
- Director, Chief Operating Officer · Stock Option (right to buy) → Common StockAcquired 96 899 @ $1,60grant · 2026-03-08
- Director · Stock Option (right to buy) → Common StockAcquired 33 435 @ $1,60grant · 2026-03-08
- Chief Medical Officer · Stock Option (right to buy) → Common StockAcquired 108 854 @ $1,60grant · 2026-03-08
- Chief Financial Officer · Stock Option (right to buy) → Common StockAcquired 61 571 @ $2,33grant · 2025-12-12
- Chief Medical Officer · Stock Option (right to purchase) → Common StockAcquired 65 676 @ $2,33grant · 2025-12-12
- Director, Chief Operating Officer · Stock Option (right to purchase) → Common StockAcquired 65 676 @ $2,33grant · 2025-12-12
- Director · Stock Option (right to purchase) → Common StockAcquired 16 234 @ $2,33grant · 2025-12-12
- Director · Stock Option (right to purchase) → Common StockAcquired 24 629 @ $2,33grant · 2025-12-12
- Director · Stock Option (right to purchase) → Common StockAcquired 19 496 @ $2,33grant · 2025-12-12
- Director · Stock Option (right to purchase) → Common StockAcquired 24 629 @ $2,33grant · 2025-12-12
- Director · Stock Option (right to purchase) → Common StockAcquired 24 629 @ $2,33grant · 2025-12-12
- Director, Chief Executive Officer · Stock Option (right to purchase) → Common StockAcquired 147 771 @ $2,33grant · 2025-12-12
- Chief Science Officer Virology · Stock Option (right to purchase) → Common StockAcquired 73 886 @ $2,33grant · 2025-12-12
- Director · Stock Option (right to purchase) → Common StockAcquired 12 770 @ $2,31grant · 2025-11-21
- Director, Chief Operating Officer · Stock Option (right to purchase) → Common StockAcquired 22 435 @ $3,01grant · 2025-10-12
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Source documents
- Traws Pharma Inc Market data — financials · 2026-05-29
- Traws Pharma Inc Market data — analyst estimates · 2026-05-29
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Iain D. DukesExecutive Chairman of the Board
Insider activity
Net buying1 buys · 0 sellsnet $998K11 insiders · last 365d
- 10% owner · Common StockBought 597 729 @ $1,67$998K · 2026-04-16
- Chief Science Officer Virology · Common StockOther 18 471 · 2025-12-12
- Chief Medical Officer · Common StockOther 16 419 · 2025-12-12
- Director, Chief Operating Officer · Common StockOther 16 419 · 2025-12-12
- Chief Financial Officer · Common StockOther 15 393 · 2025-12-12
- Director · Common StockOther 4 058 · 2025-12-12
- Director · Common StockOther 6 157 · 2025-12-12
- Director · Common StockOther 4 874 · 2025-12-12
- Director · Common StockOther 6 157 · 2025-12-12
- Director · Common StockOther 6 157 · 2025-12-12
- Director, Chief Executive Officer · Common StockOther 36 943 · 2025-12-12
Short positioning
699.9Kshares short-28.6% vs prior
3.82days to cover
18.7%short of daily vol
520fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
TRAW.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Evidence & claims
From filings & derived data- Revenue (YoY) (2025-12-31 vs 2024-12-31): 1,134.5%Derived (calculated)
- Net margin (FY 2025-12-31): 328.7%Derived (calculated)
- Return on assets (FY 2025-12-31): 86.4%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.72xDerived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 102.4%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 102.3%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 105.5%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 39.0%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 87.4%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -57.5%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -80.1%Derived (calculated)
- Operating cash flow (annual): USD -18.18MSEC XBRL filing
- Total assets (annual): USD 10.62MSEC XBRL filing
- Pre-tax income (annual): USD 9.17MSEC XBRL filing
- Total liabilities (annual): USD 11.25MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES 1SEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 1SEC XBRL filing
- Operating income (annual): USD -17.88MSEC XBRL filing
- Revenue (annual): USD 2.79MSEC XBRL filing
- Shares outstanding (annual): 9.07MSEC XBRL filing
- Current liabilities (annual): USD 11.15MSEC XBRL filing
- Current assets (annual): USD 7.98MSEC XBRL filing
- Total operating expenses (annual): USD 20.66MSEC XBRL filing
- Net income (annual): USD 9.17MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-08-02 22:31 UTCEVENTHa Price Listing TRAW remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 34 consecutive trading days (last close $0.46). cure deadline 2027-01-28 (179 days remaining).
2026-08-01 22:30 UTCEVENTHa Price Listing TRAW is DEFICIENT under NASDAQ continued-listing minimum bid: closed below $1.00 for 34 consecutive trading days (last close $0.46). cure deadline 2027-01-28 (180 days remaining).
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-04-16 00:00 UTCINSIDER4 insider transactions — 2026-04 · net buy $998k 3 derivative
2026-04-16INSIDERORBIMED ADVISORS LLC bought 597.7k sh — 10% owner ~$998k
2026-04-16INSIDERORBIMED ADVISORS LLC acquired 597.7k sh Series A Warrants (right to buy) — 10% owner
2026-04-16INSIDERORBIMED ADVISORS LLC acquired 1.79M sh Series C Warrants (right to buy) — 10% owner
2026-03-08 00:00 UTCINSIDER10 insider transactions — 2026-03 10 derivative
2026-03-08INSIDERSTOVER JACK E acquired 33.4k sh Stock Option (right to buy) — Director
2026-03-08INSIDERDukes Iain D. acquired 231.3k sh Stock Option (right to buy) — Director, Chief Executive Officer
2026-03-08INSIDERPauza Charles David acquired 118.4k sh Stock Option (right to buy) — Chief Science Officer Virology
2026-03-08INSIDERShoemaker Mary Teresa acquired 33.4k sh Stock Option (right to buy) — Director
2026-03-08INSIDERSavchuk Nikolay acquired 96.9k sh Stock Option (right to buy) — Director, Chief Operating Officer
2026-03-08INSIDERRedfield Robert acquired 108.9k sh Stock Option (right to buy) — Chief Medical Officer
2026-03-08INSIDERParker Charles Nolan acquired 104.5k sh Stock Option (right to buy) — Chief Financial Officer
2026-03-08INSIDERClarke Trafford acquired 33.4k sh Stock Option (right to buy) — Director
2026-03-08INSIDERCAUTREELS WERNER acquired 31.3k sh Stock Option (right to buy) — Director
2026-03-08INSIDERLeaman John Harold acquired 33.4k sh Stock Option (right to buy) — Director
2025-12-12 00:00 UTCINSIDER20 insider transactions — 2025-12 10 derivative
2025-12-12INSIDERPauza Charles David transacted 18.5k sh — Chief Science Officer Virology
2025-12-12INSIDERRedfield Robert transacted 16.4k sh — Chief Medical Officer
2025-12-12INSIDERSavchuk Nikolay transacted 16.4k sh — Director, Chief Operating Officer
2025-12-12INSIDERParker Charles Nolan transacted 15.4k sh — Chief Financial Officer
2025-12-12INSIDERLeaman John Harold transacted 4.1k sh — Director
Showing the 40 most recent of 59 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage